Saturday 17 October 2026
Export ANAB’s income statement to Excel — free account
AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
46.61
2.10
−4.31%
Follow ANAB
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.46 | 3.35 | 3.96 | 4.56 | |
P/FCF ratio |
0.00 | 0.00 | 47.40 | 240.58 | |
P/Operating CF |
(10.60) | (20.77) | 9.48 | (40.92) | |
P/B ratio |
0.00 | 0.00 | 24.98 | 83.21 | |
Price to Tangible BV |
0.00 | 0.00 | 24.98 | 83.21 | |
EV/Sales |
1.32 | 1.90 | 2.64 | 3.34 | |
EV/EBITDA |
0.00 | 0.00 | 13.61 | 19.34 | |
EV/Operating CF |
(1.28) | (2.22) | 31.49 | 173.44 | |
EV/FCF |
(1.27) | (2.21) | 31.63 | 176.15 | |
Quick Ratio |
8.08 | 8.52 | 8.94 | 7.49 | |
Current Ratio |
8.22 | 8.68 | 9.07 | 7.58 | |
Net Debt/EBITDA |
9.78 | (7.28) | (4.64) | 8.42 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.32 | 0.40 | 0.55 | 0.62 | |
Operating CF/Net income |
1.04 | (1.81) | 1.98 | 0.49 | |
Capex/Depreciation |
0.04 | 0.02 | 0.00 | (0.03) | |
Research and Development Expense of Revenue |
169.90% | 41.15% | 23.61% | 133.01% | |
Selling, General and Administrative Expense of Revenue |
47.65% | 13.38% | 14.59% | 102.53% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
41.50% | 12.00% | 7.86% | 55.63% | |
Graham Net Nets |
(0.21) | (0.09) | 0.02 | 0.00 | |
Graham Number |
12.51 | 8.16 | 0.00 | 0.00 | |
Earnings Yield |
(30.27%) | (13.72%) | (0.90%) | (2.30%) | |
Free Cash Flow Yield |
(30.04%) | (25.58%) | 2.11% | 0.42% | |
Revenue per Share |
0.77 | 2.74 | 3.76 | 0.89 | |
Operating CF per Share |
(1.40) | (0.98) | 3.41 | (0.90) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.40) | (0.98) | 3.41 | (0.90) | |
Cash per Share |
9.22 | 8.94 | 10.84 | 9.98 | |
Shareholders Equity per Share |
(1.55) | (1.06) | 1.29 | 0.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.55) | (1.06) | 1.29 | 0.44 | |
Free Cash Flow |
(40.28) | (27.37) | 98.00 | (25.94) | |
Working Capital |
256.38 | 292.55 | 311.63 | 274.41 | |
Capital Expenditures |
(0.04) | (0.01) | 0.00 | (0.02) | |
Net Current Asset Value |
(88.08) | (51.86) | 23.07 | (0.83) | |
EV/EBIT |
0.00 | 0.00 | 12.95 | 19.04 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 19.41 | 26.00 | |
| Other line items | |||||
Average Receivables |
15.21 | 43.94 | 37.31 | 21.82 | |
Average Payables |
4.11 | 3.24 | 3.94 | 6.82 | |
Average Assets |
381.31 | 423.26 | 424.11 | 375.87 | |
Average Common Equity |
(17.43) | 27.48 | 54.04 | 23.38 |
Columns are period end dates